CONTEXT: Statins are widely prescribed for primary and secondary prevention of ischemic cardiac and cerebrovascular disease. Although serious adverse effects are uncommon, results from a recent clinical trial suggested increased risk of intracerebral hemorrhage (ICH) associated with statin use. For patients with baseline elevated risk of ICH, it is not known whether this potential adverse effect offsets the cardiovascular and cerebrovascular benefits. OBJECTIVE: To address the following clinical question: Given a history of prior ICH, should statin therapy be avoided? DESIGN: A Markov decision model was used to evaluate the risks and benefits of statin therapy in patients with prior ICH. MAIN OUTCOME MEASURE: Life expectancy, measured as quality-adjusted life-years. We investigated how statin use affects this outcome measure while varying a range of clinical parameters, including hemorrhage location (deep vs lobar), ischemic cardiac and cerebrovascular risks, and magnitude of ICH risk associated with statins. RESULTS: Avoiding statins was favored over a wide range of values for many clinical parameters, particularly in survivors of lobar ICH who are at highest risk of ICH recurrence. In survivors of lobar ICH without prior cardiovascular events, avoiding statins yielded a life expectancy gain of 2.2 quality-adjusted life-years compared with statin use. This net benefit persisted even at the lower 95% confidence interval of the relative risk of statin-associated ICH. In patients with lobar ICH who had prior cardiovascular events, the annual recurrence risk of myocardial infarction would have to exceed 90% to favor statin therapy. Avoiding statin therapy was also favored, although by a smaller margin, in both primary and secondary prevention settings for survivors of deep ICH. CONCLUSIONS: Avoiding statins should be considered for patients with a history of ICH, particularly those cases with a lobar location.
CONTEXT: Statins are widely prescribed for primary and secondary prevention of ischemic cardiac and cerebrovascular disease. Although serious adverse effects are uncommon, results from a recent clinical trial suggested increased risk of intracerebral hemorrhage (ICH) associated with statin use. For patients with baseline elevated risk of ICH, it is not known whether this potential adverse effect offsets the cardiovascular and cerebrovascular benefits. OBJECTIVE: To address the following clinical question: Given a history of prior ICH, should statin therapy be avoided? DESIGN: A Markov decision model was used to evaluate the risks and benefits of statin therapy in patients with prior ICH. MAIN OUTCOME MEASURE: Life expectancy, measured as quality-adjusted life-years. We investigated how statin use affects this outcome measure while varying a range of clinical parameters, including hemorrhage location (deep vs lobar), ischemic cardiac and cerebrovascular risks, and magnitude of ICH risk associated with statins. RESULTS: Avoiding statins was favored over a wide range of values for many clinical parameters, particularly in survivors of lobar ICH who are at highest risk of ICH recurrence. In survivors of lobar ICH without prior cardiovascular events, avoiding statins yielded a life expectancy gain of 2.2 quality-adjusted life-years compared with statin use. This net benefit persisted even at the lower 95% confidence interval of the relative risk of statin-associated ICH. In patients with lobar ICH who had prior cardiovascular events, the annual recurrence risk of myocardial infarction would have to exceed 90% to favor statin therapy. Avoiding statin therapy was also favored, although by a smaller margin, in both primary and secondary prevention settings for survivors of deep ICH. CONCLUSIONS: Avoiding statins should be considered for patients with a history of ICH, particularly those cases with a lobar location.
Authors: H C O'Donnell; J Rosand; K A Knudsen; K L Furie; A Z Segal; R I Chiu; D Ikeda; S M Greenberg Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: Daniel Woo; Laura R Sauerbeck; Brett M Kissela; Jane C Khoury; Jerzy P Szaflarski; James Gebel; Rakesh Shukla; Arthur M Pancioli; Edward C Jauch; Anil G Menon; Ranjan Deka; Janice A Carrozzella; Charles J Moomaw; Robert N Fontaine; Joseph P Broderick Journal: Stroke Date: 2002-05 Impact factor: 7.914
Authors: Mark H Eckman; Jonathan Rosand; Katherine A Knudsen; Daniel E Singer; Steven M Greenberg Journal: Stroke Date: 2003-06-12 Impact factor: 7.914
Authors: Daniel Woo; Ranjan Deka; Guido J Falcone; Matthew L Flaherty; Mary Haverbusch; Sharyl R Martini; Steven M Greenberg; Alison M Ayres; Laura Sauerbeck; Brett M Kissela; Dawn O Kleindorfer; Charles J Moomaw; Christopher D Anderson; Joseph P Broderick; Jonathan Rosand; Carl D Langefeld; Jessica G Woo Journal: Stroke Date: 2013-09-05 Impact factor: 7.914
Authors: Fazeel M Siddiqui; Carl D Langefeld; Charles J Moomaw; Mary E Comeau; Padmini Sekar; Jonathan Rosand; Chelsea S Kidwell; Sharyl Martini; Jennifer L Osborne; Sonja Stutzman; Christiana Hall; Daniel Woo Journal: Stroke Date: 2017-06-29 Impact factor: 7.914
Authors: Jan F Scheitz; Rachael L MacIsaac; Azmil H Abdul-Rahim; Bob Siegerink; Philip M Bath; Matthias Endres; Kennedy R Lees; Christian H Nolte Journal: Neurology Date: 2016-03-25 Impact factor: 9.910
Authors: Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover Journal: Neurocrit Care Date: 2013-04 Impact factor: 3.210